Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corrado Barbui

Showing results (161-170 of 460) with videos related to

Pageof 46
Sort By:
Schizophrenia Bulletin|April 26, 2008
Does the addition of a second antipsychotic drug improve clozapine treatment?Corrado Barbui, Alessandra Signoretti, Serena Mulè, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 10, 2005
International dosage differences in fluoxetine clinical trialsScott Patten, Andrea Cipriani, Paolo Brambilla, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 24, 2007
Long-term treatment of depression with antidepressants: a systematic narrative reviewToshi A Furukawa, Andrea Cipriani, Corrado Barbui, et al.
European Journal of Clinical Pharmacology|January 9, 2017
Can systematic reviews contribute to regulatory decisions?Corrado Barbui, Antonio Addis, Laura Amato, et al.
The Cochrane Database of Systematic Reviews|April 24, 2018
Antidepressants for the treatment of depression in people with cancerGiovanni Ostuzzi, Faith Matcham, Sarah Dauchy, et al.
JAMA Network Open|August 20, 2024
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and SuicidalityGeorgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
The Lancet Regional Health. Europe|April 20, 2026
Implementation and effectiveness of the WHO Self-Help Plus (SH+) intervention in the Gaza Strip: a prospective hybrid type 1 non-randomised studyYasser Abujamei, Federico Tedeschi, Marianna Purgato, et al.
Psychotherapy and Psychosomatics|August 28, 2020
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting SystemChiara Gastaldon, Emanuel Raschi, John M Kane, et al.
Epidemiology and Psychiatric Sciences|November 26, 2019
On the need for epidemiology in psychiatric sciencesCorrado Barbui, Oye Gureje, Scott B Patten, et al.
Psychotherapy and Psychosomatics|October 22, 2020
Reply to the Comments by Doherty et alChiara Gastaldon, Emanuel Raschi, John M Kane, et al.
Pageof 46

Showing results (161-170 of 460) with videos related to

Sort By:
Pageof 46
Schizophrenia Bulletin|April 26, 2008
Does the addition of a second antipsychotic drug improve clozapine treatment?Corrado Barbui, Alessandra Signoretti, Serena Mulè, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|March 10, 2005
International dosage differences in fluoxetine clinical trialsScott Patten, Andrea Cipriani, Paolo Brambilla, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 24, 2007
Long-term treatment of depression with antidepressants: a systematic narrative reviewToshi A Furukawa, Andrea Cipriani, Corrado Barbui, et al.
European Journal of Clinical Pharmacology|January 9, 2017
Can systematic reviews contribute to regulatory decisions?Corrado Barbui, Antonio Addis, Laura Amato, et al.
The Cochrane Database of Systematic Reviews|April 24, 2018
Antidepressants for the treatment of depression in people with cancerGiovanni Ostuzzi, Faith Matcham, Sarah Dauchy, et al.
JAMA Network Open|August 20, 2024
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and SuicidalityGeorgios Schoretsanitis, Stefan Weiler, Corrado Barbui, et al.
The Lancet Regional Health. Europe|April 20, 2026
Implementation and effectiveness of the WHO Self-Help Plus (SH+) intervention in the Gaza Strip: a prospective hybrid type 1 non-randomised studyYasser Abujamei, Federico Tedeschi, Marianna Purgato, et al.
Psychotherapy and Psychosomatics|August 28, 2020
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting SystemChiara Gastaldon, Emanuel Raschi, John M Kane, et al.
Epidemiology and Psychiatric Sciences|November 26, 2019
On the need for epidemiology in psychiatric sciencesCorrado Barbui, Oye Gureje, Scott B Patten, et al.
Psychotherapy and Psychosomatics|October 22, 2020
Reply to the Comments by Doherty et alChiara Gastaldon, Emanuel Raschi, John M Kane, et al.
Pageof 46